Asset / Drug

Nivolumab

Drug and asset intelligence for Nivolumab with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Stage: Development stage unavailable

Sponsor company

Bristol-Myers Squibb →

Mechanism of action

Immunotherapy

Recent signals(4)

ClinicalJune 18, 2026

Phase II Trial of Nivolumab for Persistent Cervical Cancer Shows Potential Efficacy

A phase II trial is evaluating the efficacy and side effects of nivolumab in patients with persistent, recurrent, or metastatic cervical cancer.

ClinicalJune 18, 2026

Nivolumab Phase III Trial for High Risk Stage II-IIIB Anal Cancer Initiated

A phase III trial is underway to evaluate the efficacy of nivolumab following combined modality therapy in high risk stage II-IIIB anal cancer patients.

ClinicalJune 18, 2026

Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer

A phase III trial is evaluating the efficacy of nivolumab following surgery and chemotherapy in patients with stage IB-IIIA non-small cell lung cancer.

ClinicalJune 12, 2026

Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma

A first-in-human phase I/IIa trial is evaluating the safety and efficacy of [212Pb]VMT01, an alpha-particle therapy, in combination with nivolumab for advanced melanoma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Melanoma →

Therapeutic areas

Immunotherapy →

Melanoma →

Monoclonal Antibodies →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.